It is over

Discussion in 'Neurocrine' started by anonymous, Dec 14, 2019 at 1:51 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    On December 14, 2019, Pfizer announced 11 BILLION acquisition agreement with Neurocrine Biosciences, Inc. (NBIX) to develop and market first-in-class treatments for epilepsy. Neurocrine Biosciences has an exclusive license to XEN901, a clinical stage selective Nav1.6 sodium channel inhibitor with potential in SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other forms of epilepsy, including focal epilepsy.
     

  2. anonymous

    anonymous Guest

    Where did you see this information?
     
  3. anonymous

    anonymous Guest

    Avanair news blog
     
  4. anonymous

    anonymous Guest

    We acquired a shit epilepsy product. I asked former Epileptologist that I used to call on and they said it’s a terd. Great another crap drug
     
  5. anonymous

    anonymous Guest

    Yes, if you are an old fart at this company, Pfizer will make sure you get laid off.